Productized Offerings

Transtoxbio

Transcell has pioneered an innovative and revolutionary animal-free testing strategy (patent protected) to implement as Digital Animal Replacement Technology (DART) – An Enterprise Solution. This technology is designed to be easily adopted by global bio/pharma companies at various stages of their discovery and development functions. It aligns with the recent FDA Modernization Act 2.0 and the international ban on testing cosmetics on animals, encouraging the use of non-animal cruelty-free testing platforms

Key features of this offering include:

The use of AI/ML-powered digital workstations with prediction models to automate safety or efficacy tests
Stem cell-based MicroPhysiological in vitro systems that produce human-relevant readouts as clinical surrogate data points when treated with test agents
Integration into the end-user’s existing workflows to support discovery, development, and manufacturing processes
Benefits such as phasing out animal testing protocols and building a brand as an ethical organization
Alignment with the 3Rs in animal testing (Replace, Reduce, Refine)
Assays offered as modules under a single Application Programming Interface
- Screening – Phenotype Based – Libraries/Hits
- Screening – Lead molecules
- Potency Assessments
- Safety Pharmacology Testings
- Immunogenicity-Antigenicity Assessment
- Biologics Testings
- Ex vivo Clinical Trials
- Product Potency Measurement
- In vitro Pharmacology Assays in Drug Development

DART: An Animal-Free Testing Alternative
DART: Upholding the Principles of 3Rs—Replacement, Reduction, and Refinement

Backed by Transcell’s breakthrough scientific innovation in animal-free testing strategy, Quantiphi, with strategic partnerships with technology leaders such as Google Cloud, Amazon Web Services, and NVIDIA, combined with its commitment to HIPAA compliance and ethical AI solutions, ensures that its practices are cutting-edge and compliant with industry standards.